Bortezomib and KPT330 Combination Therapy for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current proteasome inhibitors, such as bortezomib, exhibit minimal clinical activity as a monotherapy for solid tumors, including colorectal cancer, and there is a need for new approaches to enhance therapeutic efficacy, particularly in treating cancers with wild type p53.
Innovation Solution
A pharmaceutical composition combining a proteasome inhibitor, like bortezomib, with a nuclear export inhibitor, specifically a CRM1 inhibitor like KPT330, to synergistically induce apoptosis and cell cycle arrest in cancer cells by inhibiting nuclear export and restoring p53 function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If proteasome inhibitors such as bortezomib are used as monotherapy for solid tumors, then the treatment approach is simple, but the clinical activity is minimal
Solution Approach 1:
The patent combines proteasome inhibitors with nuclear export inhibitors (specifically CRM1 inhibitors like KPT330) to create a combination therapy that synergistically enhances anti-tumor activity. This merging of two different mechanisms of action resolves the contradiction by maintaining operational simplicity through a defined combination protocol while dramatically improving clinical activity through synergistic effects on p53-containing proteins.
2Reliability
If proteasome inhibitors are combined with multiple anti-tumor strategies, then the therapeutic efficacy is enhanced, but the treatment complexity increases
Solution Approach 1:
The nuclear export inhibitor component serves multiple functions: it blocks CRM1-mediated export of p53 and other tumor suppressors, it synergizes with proteasome inhibitors, and it addresses the specific mechanism of p53 degradation in solid tumors. This multi-functionality allows enhanced therapeutic efficacy without proportionally increasing treatment complexity, as one agent (nuclear export inhibitor) accomplishes multiple therapeutic objectives.
3Object-generated harmful factors
If CRM1 is upregulated in cancers, then nuclear export of tumor suppressors is enhanced, but the use of specific CRM1 inhibitors provides broad anti-tumor activity
Solution Approach 1:
The patent converts the harmful upregulation of CRM1 (which causes tumor suppressor inactivation) into a therapeutic opportunity by using specific CRM1 inhibitors. The same molecular pathway that generates harm (CRM1-mediated export of p53) becomes the target for intervention, transforming the disease mechanism into a vulnerability that can be exploited for broad anti-tumor activity across multiple cancer types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of bortezomib and KPT330 significantly increases inhibition of cancer cell growth, inducing apoptosis and cell cycle block in p53+/+ cells, with KPT330 sensitizing CRC cells to proteasome inhibitor-induced effects, leading to enhanced anti-tumor activity in both in vitro and in vivo models.
Implementation Method 1
proteasome inhibitors such as bortezomib are able to induce growth arrest and apoptosis in CRC cells in vitro
Implementation Method 2
specific CRM-1 inhibitor KPT330 (Selinexor) has broad anti-tumor activity in various tumors
Implementation Method 3
The combination of bortezomib and KPT330 significantly increases inhibition of cancer cell growth, inducing apoptosis and cell cycle block in p53+/+ cells
Data Source
AI summary
The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.